Please use this identifier to cite or link to this item:
http://repositorio.ufla.br/jspui/handle/1/41262| metadata.artigo.dc.title: | May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications? |
| metadata.artigo.dc.creator: | Adamowicz, Jan Juszczak, Kajetan Drewa, Tomasz |
| metadata.artigo.dc.subject: | COVID-19 5-alpha-reductase inhibitors |
| metadata.artigo.dc.publisher: | Elsevier |
| metadata.artigo.dc.date.issued: | Jul-2020 |
| metadata.artigo.dc.identifier.citation: | ADAMOWICZ, J.; JUSZCZAK, K.; DREWA, T. May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications? Medical Hypotheses, [S.l.], v. 140, July 2020. |
| metadata.artigo.dc.description.abstract: | COVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females. Based on this observation, our proposed hypothesis is that 5-alpha-reductase inhibitors, that are commonly used for BPH treatment, may be one of the factors contributing to poorer prognosis in males. |
| metadata.artigo.dc.identifier.uri: | https://www.sciencedirect.com/science/article/abs/pii/S0306987720305909 http://repositorio.ufla.br/jspui/handle/1/41262 |
| metadata.artigo.dc.language: | en_US |
| Appears in Collections: | FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19) |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.